A clinical validation study of the 18-gene MyProstateScore 2.0 (MPS2) test using first-catch urine samples showed the tool may effectively identify patients who can safely avoid unnecessary prostate biopsies without requiring digital rectal examination (DRE), while maintaining high sensitivity for the detection of clinically significant prostate cancer. Researchers demonstrated that the test improved biopsy avoidance compared to prostate-specific antigen (PSA) testing and the Prostate Cancer Prevention Trial risk calculator (PCPTrc), particularly in patients considering repeat biopsy. The findings suggest that MPS2 testing without DRE requirement could provide a practical first-line test after PSA, aiding in determining the need for more invasive procedures while maintaining reliable detection of clinically significant prostate cancer.